Within the last quarter, Rain Oncology (NASDAQ:RAIN) has observed the following analyst ratings:
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 3 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 0 | 0 | 0 |
In the last 3 months, 8 analysts have offered 12-month price targets for Rain Oncology. The company has an average price target of $10.91 with a high of $19.00 and a low of $1.50.
Below is a summary of how these 8 analysts rated Rain Oncology over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This current average represents a 35.82% decrease from the previous average price target of $17.00.
Stay up to date on Rain Oncology analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.